Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svetlana Nihtyanova

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Healthcare Informatics Research|December 12, 2018
Nearest Consensus Clustering Classification to Identify Subclasses and Predict DiseaseAwad A Alyousef, Svetlana Nihtyanova, Chris Denton, et al.
Clinical Immunology (Orlando, Fla.)|February 17, 2019
Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosisCorrado Campochiaro, Simon Lytton, Svetlana Nihtyanova, et al.
The Journal of Rheumatology|August 17, 2011
Clinical and serological hallmarks of systemic sclerosis overlap syndromesAngela Pakozdi, Svetlana Nihtyanova, Pia Moinzadeh, et al.
Arthritis and Rheumatism|June 30, 2007
Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory modelLynne Shand, Mark Lunt, Svetlana Nihtyanova, et al.
Annals of the Rheumatic Diseases|May 16, 2012
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosisKorsa Khan, Shiwen Xu, Svetlana Nihtyanova, et al.
Rheumatology (Oxford, England)|December 15, 2010
Registries in systemic sclerosis: a worldwide experienceFelice Galluccio, Ulrich A Walker, Svetlana Nihtyanova, et al.
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort studyGabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
Rheumatology (Oxford, England)|May 13, 2017
Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR groupVeronika K Jaeger, Oliver Distler, Britta Maurer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Healthcare Informatics Research|December 12, 2018
Nearest Consensus Clustering Classification to Identify Subclasses and Predict DiseaseAwad A Alyousef, Svetlana Nihtyanova, Chris Denton, et al.
Clinical Immunology (Orlando, Fla.)|February 17, 2019
Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosisCorrado Campochiaro, Simon Lytton, Svetlana Nihtyanova, et al.
The Journal of Rheumatology|August 17, 2011
Clinical and serological hallmarks of systemic sclerosis overlap syndromesAngela Pakozdi, Svetlana Nihtyanova, Pia Moinzadeh, et al.
Arthritis and Rheumatism|June 30, 2007
Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory modelLynne Shand, Mark Lunt, Svetlana Nihtyanova, et al.
Annals of the Rheumatic Diseases|May 16, 2012
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosisKorsa Khan, Shiwen Xu, Svetlana Nihtyanova, et al.
Rheumatology (Oxford, England)|December 15, 2010
Registries in systemic sclerosis: a worldwide experienceFelice Galluccio, Ulrich A Walker, Svetlana Nihtyanova, et al.
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort studyGabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
Rheumatology (Oxford, England)|May 13, 2017
Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR groupVeronika K Jaeger, Oliver Distler, Britta Maurer, et al.
Pageof 1